In 2022, the global anti-viral drugs market is expected to be worth $59,596.8 million. The introduction of generic antiviral medicines, as well as increased awareness about the availability of various vaccines for viral infections, are affecting growth throughout the forecast period. Between 2022 and 2032, the overall demand for Anti-Viral Drugs is expected to grow at a CAGR of 3.9%, reaching around US$ 87,675.36 Million.
Request Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1951
Anti-viral drugs are medications that are specifically used to treat viral infections. Most anti-viral drugs, like antibiotics, are used to treat specific viral infections, whereas a broad-spectrum anti-viral drug is effective against a wide range of viruses. Antiviral drugs do not kill their target pathogens; instead, they inhibit their growth.
The global anti-viral drugs market is expected to grow at a moderate rate in the pharmaceutical market due to increased awareness, an increase in diseased population, and the introduction of new drugs with improved efficacy.
Several major patents, including Combivir, Sustiva, Tenofovir, Tamiflu, Relenza, and Telbivudine, will expire during the forecast period. The patent expirations of these blockbuster drugs are expected to spark generic competition in the antivirals therapeutics market, making it more competitive.
Late-stage pipeline drugs are expected to enter the market, positively affecting the market. Most antivirals are considered relatively harmless to the host and are thus used to treat infections. They differ from viricides, which are not medications but can destroy or deactivate virus particles both outside and inside the body.
Anti-viral drugs are used to treat patients with herpes viruses, HIV, influenza A and B viruses, and hepatitis B and C viruses.
Anti-viral Drugs Market: Drivers and Restraints
According to WHO, approximately 35.3 million people worldwide were infected with HIV as of October 2013. As a result, increased viral infection incidences are one of the key factors driving the growth of the anti-viral drugs market. Newer and more advanced treatments and formulations, such as vaccines, combination therapy, and others, are being introduced to the market as a result of the strong R&D activities.
Get a Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-1951
As a result, one of the critical factors in the growth of the anti-viral drugs market is strong R&D. On the other hand, high failure risk, high R&D and therapy costs, and government austerity are some of the threats expected to stymie market growth.
These are some of the factors that are expected to drive the growth of the global anti-viral drugs market between 2016 and 2026. However, the market’s main challenges are the increasing use of natural products and the high cost of developing drugs.
Anti-viral Drugs Market: Overview
Didanosine, zidovudine, lamivudine, and stavudine currently dominate the generic market for anti-viral drugs. Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales drove the overall anti-viral drug market, accounting for more than half of the market share in 2010.
By the end of 2012, 9.7 million people in low- and middle-income countries were receiving antiretroviral therapy (ART). According to WHO, the number of patients on ART increased by 1.6 million in 2012, the largest increase in a single year.
Nearly four out of five people were freshly put on treatment in the sub-Saharan Africa. In 21 African countries with a high burden of HIV, two out of three people in need are receiving treatment, and two out of three positive pregnant women are receiving antiretroviral drugs to prevent HIV transmission to their infants.
Anti-viral Drugs Market: Regional Overview
Region wise, the global anti-viral drugs market is classified into regions namely, North America, Eastern Europe, Western Europe, Latin America, Japan, Asia-Pacific, Middle East and Africa. According to WHO, in countries with Major ART scale-up such as Brazil or China, the death rate among people living with HIV has decreased by 80%. In 2015, in India the number of people living with HIV were 2.1 Million and in U.S. the number was around 1.2 Million in the year 2013.
Anti-viral Drugs Market: Key Players
Some of the key players in global anti-viral drugs market, which are focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, include Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, AstraZeneca, Cipla, Schering-Plough, Johnson & Johnson, Merck & Co and others.
Request For Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-1951
Key Segments Covered in the Anti-Viral Drugs Industry Analysis
Anti-Viral Drugs Market by Product type:
- Hepatitis-C antivirals
- HIV antivirals
- Herpes antivirals
- Hepatitis-B antivirals
- Influenza antivirals
- Others (Pneumonia, Flu, etc.)
Anti-Viral Drugs Market by End-user:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs